In 2020, the added value of industrial enterprises above designated size rose by 0.3 percent year on year, and the output value of the industry exceeded RMB 60 billion. The technology of such protein drugs as recombinant human granulocyte-macrophage colony-stimulating factor and its market share took the lead in China. In addition, bio-pharmaceutical technologies such as an Escherichia coli-derived virus-like particle-based vaccine, a recombinant hepatitis E vaccine, and a recombinant human papillomavirus vaccine all held world leading positions.
Fujian has been committed to innovative development with local features, with a focus on biological drugs, chemical drugs, traditional Chinese medicine, medical devices, and bio-manufacturing industries.
Biological Drugs
Chemical Drugs
Traditional Chinese Medicine
Medical Devices
Bio-manufacturing
Key Investment Promotion Projects
The former Caimao Garment Mall was renovated and upgraded. A bio-pharmaceutical science and technology park with a carrier area of 150,000sqm will be constructed as the carrier for investment promotion in the bio-pharmaceutical and medical instrument industry. Estimated investment of RMB 1 billion.
The project has a total covering area of about 76mu. It is expected to become an industrialization and model base for Internet+ medical service, pharmaceutical and medical device R&D, etc. Estimated investment of RMB 770 million.
Capitalize on the opportunity of the joint development of a regional medical center of traumatic orthopedics with Shanghai No. 6 People's Hospital to attract a series of hi-tech medical device enterprises, develop a high-end medical industrial service platform and develop an industrial cluster of medical equipment R&D, production and sale, primarily including orthopaedic treatment devices. The estimated investment amount depends on project conditions.
Attract production lines of sequoyitol derivative preparation that is an anti-diabetes new drug. Mingxi County has rich Chinese yew resources with a planting area of over 3,000mu now. Estimated investment of RMB 200 million.
Avail the advantageous private medical resources of Putian to plan and construct a medical device and bio-pharmaceutical R&D and production base, headquarters base and warehousing and logistics base. Estimated investment of RMB 3 billion.
Attract and produce medical device enterprises with a high technical intensity, including intelligent recuperation, medical cosmetics, middle and high-end in-vitro diagnostic reagent, high-value medical consumables, etc. Estimated investment of RMB 5 billion.
With a planned covering area of about 250mu, this project primarily produce medical and fitness equipment, including sleep monitor, body temperature monitor, cloud blood pressure gauge, dynamic analytical instrument, low-temperature freezing equipment, dialysis equipment, first-aid device, laser operation instrument, ultrasonic operation and therapeutic device, recuperation machinery, handicapped deviice, etc. Estimated investment of RMB 600 million.
It is expected to avail the cross-strait resources in the greater health sector to develop a greater health model park with a concentration of cross-strait medium and small-size health enterprises. Estimated investment of RMB 1.5 billion.
Investment Carrier